ISSWSH Sexual Pain Course 2020
ISSWSH Fall Course 2020
ISSWSH Annual Meeting 2021
March 4-7, 2021 340 days left
Renaissance Dallas Hotel, Dallas, TX, USA
ISSWSH has decided to cancel the ISSWSH Sexual Pain Course scheduled for April 17-18, 2020 in Washington D.C. in direct response to the novel coronavirus (COVID-19) outbreak which is now identified as a pandemic. ISSWSH is concerned for the health and safety of our faculty and attendees and recognizes that there are an increasing number of academic institutions restricting travel which affects people’s ability to attend. For more information on this cancellation and any questions you may have, please visit: https://www.isswshcourse.org/spring2020/covid-19/cancellation
At the 2020 Annual Business Meeting, ISSWSH welcomed Dr. Noel N. Kim, PhD, IF, Senior Investigator at the Institute for Sexual Medicine in San Diego and associate editor of Sexual Medicine Reviews (SMR), as its new president for a two-year term 2020-2022. He previously served as the Assistant Director of the Laboratory for Sexual Medicine Research at the Boston University School of Medicine and was a member of the editorial board of The Journal of Sexual Medicine for the first decade of the journal through 2014. From 2007, Dr. Kim served for 5 years as Chief Scientific Officer of Alagin Research, a biotechnology company devoted to developing therapeutics and diagnostics in sexual medicine. Dr. Kim continues to serve as a consultant to other companies developing therapies for sexual dysfunction. Dr. Kim most recently served as the society’s President-Elect, and Treasurer before that.Read more ...
ISSWSH is pleased to provide the following updates related to therapies for Hypoactive Sexual Desire Disorder or HSDD. The FDA has updated prescribing information for flibanserin, removed the REMS certification requirement for prescribers and pharmacists, and updated safety information related to the alcohol contraindication. In addition, bremelanotide has now been approved for treatment of HSDD. Please see the attached news release related to these two therapies for more specific information and references.